Breheret M, Lubgan D, Haderlein M, et al. - Since single-cycle induction chemotherapy can help maintain a low local rate of recurrence while maintaining manageable overall toxicity, researchers analyzed long-term tumor location data on single-cycle induction chemotherapy (IC) response. For this investigation, patients with functionally inoperable primary HNSCC of the larynx (n = 43), hypopharynx (n = 42) or mesopharynx/tongue (n = 17) received one cycle of docetaxel (75 mg/m², d1) plus cisplatin (30 mg/m², d1-3) or carboplatin (AUC 1.5, d1-3) and a response evaluation 3 weeks later. Data reported that the overall response rate was 72.5% and the overall 10-year local recurrence-free survival was 73.7%. A single-cycle HNSCC induction chemotherapy enables both surgery plus adjuvant therapy and chemoradiotherapy. Long-term control of local and remote disease was great, but it differed between larynx tumors and mesopharynx/tongue vs hypopharynx.